Focused Issues more

Vol 4, No 6(December 2015): Lung Cancer Immunotherapy More >>
Vol 4, No 5 (October 2015): Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient... More >>
Vol 4, No 4 (August 2015): Improving the Quality and Outcomes of Lung Cancer Care: An... More >>

Sponsored by

Translational Lung Cancer Research is sponsored by Nanjing General Hospital of Nanjing Military Command, Nanjing, China

Sponsored by

Preface on Small Cell Lung Cancer

Preface on small cell lung cancer
Niki Karachaliou, Daniela Morales-Espinosa

Review Article on Small Cell Lung Cancer

Cellular and molecular biology of small cell lung cancer: an overview
Niki Karachaliou, Sara Pilotto, Chiara Lazzari, Emilio Bria, Filippo de Marinis, Rafael Rosell
Cancer stem cells in small cell lung cancer
Jordi Codony-Servat, Alberto Verlicchi, Rafael Rosell
Treatment for small cell lung cancer, where are we now?—a review
Gabriela Alvarado-Luna, Daniela Morales-Espinosa
Small cell lung cancer (SCLC): no treatment advances in recent years
Filippos Koinis, Athanasios Kotsakis, Vasileios Georgoulias
Targeted drugs in small-cell lung cancer
Mariacarmela Santarpia, Maria Grazia Daffinà, Niki Karachaliou, Maria González-Cao, Chiara Lazzari, Giuseppe Altavilla, Rafael Rosell

Original Article on Small Cell Lung Cancer

Second-line therapy for small cell lung cancer: exploring the potential role of circulating tumor cells
Gerhard Hamilton, Barbara Rath, Sophia Holzer, Maximilian Hochmair

Editorial

Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer
Hidehito Horinouchi
Surgical controversies in mesothelioma: MesoVATS addresses the role of surgical debulking
Chuong D. Hoang
AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials
Ignacio Gil-Bazo, Christian Rolfo
Raising the bar for enthusiasm when looking at results of randomized phase II trials—the case of sunitinib in small-cell lung cancer
Massimo Di Maio, Paolo Bironzo, Giorgio Vittorio Scagliotti
AZD9291 in epidermal growth factor receptor inhibitor—resistant non-small-cell lung cancer
Thomas E. Stinchcombe
Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?
Jon Zugazagoitia, Santiago Ponce, Luis Paz-Ares
Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer?
Kosuke Takahashi, Hiroshi Saito
Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a word of caution
Gonzalo Varela, María Teresa Gómez-Hernández
The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung
Wan Ling Tan, Quan-Sing Ng
Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?
Giuseppe Lo Russo, Claudia Proto, Marina Chiara Garassino
Overall survival in non-small cell lung cancer—what is clinically meaningful?
Klaus Fenchel, Ludger Sellmann, Wolfram C. M. Dempke

Review Article

PiggyBac transposon vectors: the tools of the human gene encoding
Shuang Zhao, Enze Jiang, Shuangshuang Chen, Yuan Gu, Anna Junjie Shangguan, Tangfeng Lv, Liguo Luo, Zhenghong Yu

Letter to the Editor

Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target
Domenico Galetta, Annamaria Catino, Andrea Misino

Case Report

Metachronous primary uterine cancer surgically resected during crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma
Annamaria Catino, Andrea Misino, Anna Scattone, Lucia Caldarola, Stella Petroni, Antonio Logroscino, Elisabetta Sara Montagna, Gabriella Serio, Giovanni Simone, Domenico Galetta

Maintenance Therapy

Maintenance therapy in non-small cell lung cancer
Gerald Schmid-Bindert

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?
Yoshihisa Kobayashi, Tetsuya Mitsudomi
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach
Javier de Castro Carpeño, Cristóbal Belda-Iniesta
Irreversible EGFR-TKIs: dreaming perfection
Lorenza Landi, Federico Cappuzzo
Angiogenesis in cancer: anti-VEGF escape mechanisms
Gerald W. Prager, Marina Poettler, Matthias Unseld, Christoph C. Zielinski
MET inhibition in lung cancer
Jessica Menis, Matteo Giaj Levra, Silvia Novello
Activated RET and ROS: two new driver mutations in lung adenocarcinoma
Marc Bos, Masyar Gardizi, Hans-Ulrich Schildhaus, Reinhard Buettner, Juergen Wolf
Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Lothar R Pilz, Christian Manegold, Gerald Schmid-Bindert
Potential toxicities of prophylactic cranial irradiation
Frank A. Giordano, Grit Welzel, Yasser Abo-Madyan, Frederik Wenz
ALK and ROS1 as a joint target for the treatment of lung cancer: a review
Raimon Puig de la Bellacasa, Niki Karachaliou, Roger Estrada-Tejedor, Jordi Teixidó, Carlota Costa, José I. Borrell
HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches
Ana Christina Garrido-Castro, Enriqueta Felip
From tissue to molecular phenotyping: Pre-analytical requirements
Thomas R. Muley, Felix JF. Herth, Philipp A. Schnabel, Hendrik Dienemann, Michael Meister
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors
José Miguel Sánchez-Torres, Santiago Viteri, Miguel Angel Molina, Rafael Rosell
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Are three doses of SABR (stereotactic ablative radiotherapy) more effective than 30 doses of conventional radiotherapy?
Anna O. Simeonova, Katharina Fleckenstein, Hans-Jörg Wertz, Judit Boda-Heggemann, Frederik Wenz
Cetuximab in non-small-cell lung cancer
Robert Pirker, Martin Filipits
FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications
Hans-Ulrich Schildhaus, Lucia Nogova, Jürgen Wolf, Reinhard Buettner
MET inhibitors in combination with other therapies in non-small cell lung cancer
Sukhmani Padda, Joel W. Neal, Heather A. Wakelee
Adaptive resistance to targeted therapies in cancer
Rafael Rosell, Niki Karachaliou, Daniela Morales-Espinosa, Carlota Costa, Miguel Angel Molina, Irene Sansano, Amaya Gasco, Santiago Viteri, Bartomeu Massuti, Jia Wei, María González Cao, Alejandro Martínez Bueno
Inhibition of insulin-like growth factor receptor: end of a targeted therapy?
Rathi N. Pillai, Suresh S. Ramalingam

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper
Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice
Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Original Article

BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
Hyojin Kim, Jin-Haeng Chung

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis
Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

Editorials

Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung
Pedro Mendez, Jose Luis Ramirez
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Currently no content available!